Urdorf (ots) - Nach der Weltpremiere des neuen A110 am Automobilsalon Genf 2017 bereitet Alpine Schritt ...
Value of Text Verification Tool (TVT) Strongly Confirmed at RAPS in Philadelphia
Frankfurt (ots) - Trying economic times mean tight budgets. More projects, fewer people, rigid quality standards and competitve pressures are making the computer-driven proofreading tool made by Schlafender Hase more valuable than ever.
Schlafender Hase GmbH of Frankfurt reported that an analyis of discussions with professionals attending the annually RAPS event (Regulatory Affairs Professionals Society) in Philadelphia showed they often spend more time doing what they can't do than what they can do.
TVT shifts the focus from proofreading to pharmaceuticals
"Much of time-intensive proofreading activities in the regulatory afffairs context have little to do with pharmaceuticals," explained Willie Schnaubelt, managing director at Schlafender Hase. "Questions about misspelling and inconsistencies in layouts are robbing people of time that could be better spent on pharmaceutical issues. TVT makes it possible to win time for doing what they can do best, by not losing time doing proofreading chores that their computer can do more effectivly."
The human element was also a focal point at RAPS. While all agreed about the importance of flawless documentation, frustration was also expressed about the degree to which pharmaceutical skills often took a back seat to proofreading needs. As one RAPS visitor put it: "Sometimes I'm evaluated as a proofreader and not as a pharmaceuticals professional. It is an unfair situation, both to me and the product. I look to TVT as a way out of this dilemma."
TVT is the standard for the pharmaceutical industry. It supports all relevant file formats (DOC, DOCX RTF, TXT, HTML, PDF and both XML-standards PIM and SPL) and processes all major languages.
ots Originaltext: Schlafender Hase GmbH
Im Internet recherchierbar: http://www.presseportal.ch
For more information about TVT and Schlafender Hase contact:
EU: +49 69 2444-8112
US: +1 973 685-6123